How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,193 results for

Vaginal Estrogen

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Comparison between vaginal royal jelly and vaginal estrogen effects on quality of life and vaginal atrophy in postmenopausal women: a clinical trial study. Full Text available with Trip Pro

Comparison between vaginal royal jelly and vaginal estrogen effects on quality of life and vaginal atrophy in postmenopausal women: a clinical trial study. This study was conducted to evaluate the therapeutic effects of vaginal royal jelly and vaginal estrogen on quality of life and vaginal atrophy in postmenopausal women.This double-blind randomized controlled clinical trial was carried out at gynecology and obstetrics clinics of Hajar Hospital of Shahrekord University of Medical Sciences (...) (Iran) from January 2013 to January 2014. The study was conducted on married postmenopausal women between 50 and 65 years old. Of 120 patients, 30 individuals were excluded based on the exclusion criteria, and 90 women were randomly distributed into three groups of 30 royal jelly vaginal cream 15%, vaginal Premarin, and placebo (lubricant), for three months. At the beginning and the end of the study, quality of life and vaginal cytology assay were evaluated. Data were analyzed by SPSS Version 11

2017 Electronic physician Controlled trial quality: uncertain

2. The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer

with urogenital symptoms. Int J Gynaecol Obstet 2003;82:187–97. [ ] [ ] Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 2005;41:2673–81. [ ] Le Ray I, Dell’Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 2012;135:603–9. [ ] O’Meara ES, Rossing MA, Daling JR, Elmore JG (...) The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer - ACOG Menu ▼ The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer Page Navigation ▼ Number 659, March 2016 (Reaffirmed 2018) Committee on Gynecologic Practice This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Gynecologic

2016 American College of Obstetricians and Gynecologists

3. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. (Abstract)

17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. The efficacy and safety of 25-μg 17β-estradiol vaginal tablets (Vagifem) were assessed and compared with 1.25-mg conjugated equine estrogen vaginal cream (Premarin Vaginal Cream) for the relief of menopausal-derived atrophic vaginitis, resulting from estrogen deficiency.In a multicenter, open-label, randomized, parallel-group study, 159 menopausal women were treated for 24 (...) tablets rated their medication favorably than did patients who were using the vaginal cream (p ≤ 0.001). Patients who were receiving the vaginal tablets also had a lower incidence of patient withdrawal (10% versus 32%).Treatment regimens with 25-μg 17β-estradiol vaginal tablets and with 1.25-mg conjugated equine estrogen vaginal cream were equivalent in relieving symptoms of atrophic vaginitis. The vaginal tablets demonstrated a localized effect without appreciable systemic estradiol increases

2018 Menopause Controlled trial quality: uncertain

4. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. (Abstract)

A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. The aim of the study was to compare 6-month efficacy and safety for treatment of vaginal dryness/genitourinary syndrome of menopause in women undergoing fractionated CO2 vaginal laser therapy to women using estrogen vaginal cream.This multicenter, randomized trial compared fractionated CO2 laser to estrogen cream at 6 institutions. We (...) included menopausal women with significant vaginal atrophy symptoms and we excluded women with prolapse below stage 2, recent pelvic surgery, prior mesh surgery, active genital infection, history of estrogen sensitive malignancy, and other autoimmune conditions. The primary outcome was the visual analog scale vaginal dryness score. Secondary outcomes included evaluation of vaginal atrophy, quality of life symptoms, assessment of sexual function, and urinary symptoms. Adverse events (AEs) and patient

2019 Menopause

5. Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate

in December 2016. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary In a randomised controlled trial (RCT; n=332), at week 12, conjugated oestrogens and bazedoxifene 0.45 mg/20 mg statistically significantly reduced the average daily number of moderate and severe hot flushes from baseline compared with placebo. In another RCT (n=664) in women with vulvar or vaginal atrophy, at week 12, there were statistically (...) the groups was statistically significant (p<0.001) (1 RCT, n=332). In women with vulvar or vaginal atrophy, at week 12, there was a statistically significantly greater increase in vaginal superficial cells, and decrease in parabasal cells from baseline in women in the conjugated oestrogens and bazedoxifene 0.45 mg/20 mg group compared with women in the placebo group. Decreases in vaginal pH and changes in the severity of the most bothersome vulvar or vaginal symptom were not statistically significantly

2017 National Institute for Health and Clinical Excellence - Advice

6. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo. (Abstract)

Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo. In the 1-year phase 3 Selective estrogens, Menopause, And Response to Therapy-5 trial, cumulative amenorrhea rates with conjugated estrogens/bazedoxifene (CE/BZA) were similar to placebo and higher than with conjugated estrogens/medroxyprogesterone acetate (CE/MPA). This post hoc analysis reports bleeding/spotting rates in 4-week intervals (cycles) and 3-month (...) intervals (quarters) with these therapies and the percentage of cases attributable to spotting only.Generally healthy postmenopausal women with menopausal symptoms recorded vaginal bleeding/spotting in daily diaries while receiving CE 0.45 mg/BZA 20 mg, CE 0.625 mg/BZA 20 mg, CE 0.45 mg/MPA 1.5 mg, or placebo.A total of 1596 women in the modified intent-to-treat population contributed data. Incidence of bleeding/spotting was significantly (p < 0.001) lower with CE 0.45 mg/BZA 20 mg (0.54‒4.44%), CE

2018 Postgraduate medicine Controlled trial quality: uncertain

7. No vaginal estrogen therapy arm in an RCT trial on genitourinary syndrome of menopause is a concern. Full Text available with Trip Pro

No vaginal estrogen therapy arm in an RCT trial on genitourinary syndrome of menopause is a concern. 31017495 2019 11 20 1473-0804 22 4 2019 Aug Climacteric : the journal of the International Menopause Society Climacteric No vaginal estrogen therapy arm in an RCT trial on genitourinary syndrome of menopause is a concern. 426 10.1080/13697137.2019.1597842 Maher Christopher F CF a Royal Brisbane and Womens Hospital, University of Queensland , Brisbane , Australia. Biuttini Melissa M b Department

2019 Climacteric : the journal of the International Menopause Society Controlled trial quality: uncertain

8. Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial. (Abstract)

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial. We aimed to compare the efficacy of 2 commonly used contemporary vaginal estrogen administrations versus placebo for the prevention of urinary tract infection (UTI) in postmenopausal women with a clinical diagnosis of recurrent UTI (rUTI).This was an investigator-initiated, multicenter, single-blind, randomized, placebo-controlled trial of vaginal estrogen (delivered (...) via ring or cream) compared with placebo. Postmenopausal women with documented rUTI were randomized to receive either vaginal estrogen (via ring or cream) or placebo cream in a 1:1:1 fashion. The primary outcome was occurrence of UTI at 6 months. After 6 months, open-label use of ring or active cream was offered to all participants for an additional 6 months. Because of slower than expected recruitment, sample size calculations and block randomization schema were revised to combine estrogen groups

2019 Female pelvic medicine & reconstructive surgery Controlled trial quality: predicted high

9. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Full Text available with Trip Pro

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. The aim of the study was to systematically review studies that evaluated endometrial hyperplasia or cancer incidence with unopposed vaginal estrogens.PubMed and EMBASE were searched from inception to August 2017 for relevant articles and abstracts. Bibliographies of review articles and abstracts of major women's health medical meetings were examined. Eligible studies (independently reviewed by 4 (...) authors) had to report menopausal vaginal estrogen use and endometrial histology, or incidence of endometrial hyperplasia or cancer.Of 5,593 abstracts from the literature search and 47 articles from other sources, 36 articles and 2 abstracts were eligible, describing 20 randomized controlled studies, 8 interventional studies, and 10 observational studies. Collectively, the studies did not support an increased risk of endometrial hyperplasia or cancer with low-dose vaginal estrogens. Rates

2019 Menopause

10. Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women Full Text available with Trip Pro

Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women To measure the effect of vaginal estrogen cream in the treatment of vaginal atrophy in menopausal Indian women.A total of 50 menopausal women aged between 40 and 80 years old with symptoms of vaginal atrophy were selected and treated with 0.5 g vaginal estrogen cream, twice weekly for 12 weeks. The women were followed-up monthly where symptom score, Genital Health Clinical Evaluation (GHCE) score, vaginal pH (...) during the study period.Vaginal estrogen cream causes symptomatic relief in women of menopausal age in India suffering from vaginal atrophy.

2017 Oman medical journal

11. Vaginal estrogen: a dual-edged sword in postoperative healing of the vaginal wall. Full Text available with Trip Pro

Vaginal estrogen: a dual-edged sword in postoperative healing of the vaginal wall. Reconstructive surgery for pelvic organ prolapse is plagued with high failure rates possibly due to impaired healing or regeneration of the vaginal wall. Here, we tested the hypothesis that postoperative administration of local estrogen, direct injection of mesenchymal stem cells (MSCs), or both lead to improved wound healing of the injured vagina in a menopausal rat model.Ovariectomized rats underwent surgical (...) injury to the posterior vaginal wall and were randomized to treatment with placebo (n = 41), estrogen cream (n = 47), direct injection of MSCs (n = 39), or both (n = 43).MSCs did not survive after injection and had no appreciable effects on healing of the vaginal wall. Acute postoperative administration of vaginal estrogen altered the response of the vaginal wall to injury with decreased stiffness, decreased collagen content, and decreased expression of transcripts for matrix components

2017 Menopause

12. Effect of Local Estrogen Cream on Vaginal Health after Pessary Use for Prolapsed Pelvic Organ: A Randomized Controlled Trial. (Abstract)

Effect of Local Estrogen Cream on Vaginal Health after Pessary Use for Prolapsed Pelvic Organ: A Randomized Controlled Trial. Currently, there is no evidence whether local estrogen cream should always be used in conjunction with a pessary as atrophic prevention. There is still no consensus about the long-term safety of local estrogen cream. Therefore, it is recommended to use hormone for the shortest duration as possible.Evaluate the effect of local estrogen cream on vaginal health in pessary (...) use for pelvic organ prolapse.Forty postmenopausal women with pelvic organ prolapse who had used a pessary in conjunction with local estrogen cream for six weeks were randomly selected to use vaginal conjugated equine estrogen (CEE) cream 0.5 g once a week (treatment group) or no treatment (control group) for 24 weeks. The primary outcome was vaginal health assessment composed of vaginal symptom score, vaginal pH, and vaginal maturation index. The secondary outcome measures were the difficulty

2018 Journal of the Medical Association of Thailand = Chotmaihet thangphaet Controlled trial quality: predicted high

13. Application of conjugated estrogen cream in the treatment of postmenopausal atrophic vaginitis. (Abstract)

Application of conjugated estrogen cream in the treatment of postmenopausal atrophic vaginitis. To observe and analyze the effect of conjugated estrogen cream in the treatment of postmenopausal atrophic vaginitis. The 160 patients clearly diagnosed with postmenopausal atrophic vaginitis and treated in our hospital were selected as subjects and divided into study group and reference group with equal number of cases. The reference group was treated with compound metronidazole suppository, while (...) in the two groups shows that the study group has lower incidence, with statistical significance in comparison between the groups, p<0.05. Treatment of postmenopausal atrophic vaginitis with combination of conjugated estrogen cream and compound metronidazole suppository can achieve good results with high safety and reliability.

2018 Pakistan journal of pharmaceutical sciences

14. Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. Full Text available with Trip Pro

Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. To examine the associations between vaginal estrogen use and multiple health outcomes including cardiovascular disease (total myocardial infarction, stroke, and pulmonary embolism/deep vein thrombosis), cancer (total invasive, breast, endometrial, ovarian, and colorectal cancer), and hip fracture.We included postmenopausal women from the Nurses' Health Study (1982-2012) who were not current users of systemic hormone (...) therapy at the start of the study or during follow-up. Vaginal estrogen use was self-reported on the biennial questionnaires. Information on incident health outcomes were self-reported and confirmed by medical records. We used Cox proportional hazards regression to model the multivariable adjusted hazard ratios and the 95% confidence intervals for vaginal estrogen use and multiple health outcomes.Over 18 years of follow-up, after adjusting for covariates, risks for cardiovascular disease, cancer

2018 Menopause

15. Comparison of Vaginal and Transdermal Oestrogen Before Frozen Thawed Embryo Transfer

Comparison of Vaginal and Transdermal Oestrogen Before Frozen Thawed Embryo Transfer Comparison of Vaginal and Transdermal Oestrogen Before Frozen Thawed Embryo Transfer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Comparison of Vaginal and Transdermal Oestrogen Before Frozen Thawed Embryo Transfer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03518528 Recruitment Status : Recruiting First Posted : May 8, 2018 Last

2018 Clinical Trials

16. Tissue-selective estrogen complex for women who experience breast discomfort or vaginal bleeding when on hormone therapy. (Abstract)

Tissue-selective estrogen complex for women who experience breast discomfort or vaginal bleeding when on hormone therapy. The objective of this study was to evaluate the effects of switching from hormone therapy to tissue-selective estrogen complex (TSEC) in women who experience vaginal bleeding or breast discomfort.This retrospective cohort study included 82 postmenopausal women who received TSEC after switching from another hormone therapy due to adverse events. Changes in symptoms (...) and imaging after switching to TSEC were evaluated.The mean age was 56.9 years. The women were switched to TSEC due to vaginal bleeding in 56.1% and breast discomfort in 47.6% (multiple choices were allowed). After the switch, almost all women (97.6%) experienced an improvement in adverse events. However, 27% of the women had worsening of vasomotor symptoms, which was more common when hormone therapy was changed from 2 mg of estradiol (41.7%) compared with 1 mg of estradiol (16.7%), 0.625 mg of conjugated

2018 Menopause

17. Estrogen Action in the Epithelial Cells of the Mouse Vagina Regulates Neutrophil Infiltration and Vaginal Tissue Integrity Full Text available with Trip Pro

Estrogen Action in the Epithelial Cells of the Mouse Vagina Regulates Neutrophil Infiltration and Vaginal Tissue Integrity In the female reproductive tract, the innate immune system is modulated by two sex steroid hormones, estrogen and progesterone. A cyclical wave of neutrophils in the vaginal lumen is triggered by chemokines and correlates with circulating estrogen levels. Classical estrogen signaling in the female reproductive tract is activated through estrogen receptor α (encoded (...) by the Esr1 gene). To study the role of estrogen action in the vagina, we used a mouse model in which Esr1 was conditionally ablated from the epithelial cells (Wnt7acre/+; Esr1f/f). Histological evidence showed that in response to a physical stress, the lack of ESR1 caused the vaginal epithelium to deteriorate due to the absence of a protective cornified layer and a reduction in keratin production. In the absence of ESR1 in the vaginal epithelial tissue, we also observed an excess of neutrophil

2018 Scientific reports

18. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study. (Abstract)

Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study. The aim of the study was to evaluate the laboratory and endometrial safety of topical testosterone versus topical estrogen for the treatment of vaginal atrophy in postmenopausal women.This was a randomized, placebo-controlled trial of 60 postmenopausal women aged 40 to 70 years at the Menopause (...) Clinic of CAISM UNICAMP. Women were randomized into three vaginal treatment groups: estrogen, testosterone, or placebo. The treatment was applied 3 times a week for 12 weeks. Hormonal laboratory values of follicle-stimulating hormone, luteinizing hormone, estradiol, estrone, androstenedione, total testosterone, free testosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin were assessed at baseline and at 6 and 12 weeks. Metabolic laboratory values

2018 Menopause Controlled trial quality: uncertain

19. Vaginal estrogen and mammogram results: case series and review of literature on treatment of GSM in breast cancer survivors. (Abstract)

Vaginal estrogen and mammogram results: case series and review of literature on treatment of GSM in breast cancer survivors. To examine mammographic density before and after at least 1 year of vaginal estrogen use in a small cohort of healthy postmenopausal women and women with a personal history of breast cancer.We extracted data via chart review of patients from a single practitioner's menopause specialty clinic in Baltimore, MD. Mammographic change was primarily determined via the Bi-RADS (...) of local vaginal estrogen. Ospemifene use in one patient did not appear to be associated with any change in Bi-RADS score. Our narrative review found little data on the effects of vaginal estrogen therapy or newer alternative systemic therapies such as ospemifene on mammographic density.Low-dose vaginal estrogen use for 1 or more years in a small cohort of women with GSM did not appear to be associated with any changes in breast density or Bi-RADS breast cancer risk scores in the majority of study

2018 Menopause

20. Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function

Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Vaginal (...) See Sponsor: Pamela Smith Information provided by (Responsible Party): Pamela Smith, Ohio State University Study Details Study Description Go to Brief Summary: Pilot randomized, placebo-controlled trial of nulliparous postpartum women with a perineal laceration following a term vaginal delivery comparing vulvovaginal atrophy symptoms between women using vaginal estrogen in the postpartum period with those using placebo. Condition or disease Intervention/treatment Phase Vaginal Atrophy Drug

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>